CCL5 and metabolic dysfunction-associated steatotic liver disease: Importantly, pharmacological inhibition of the receptors of CCL5 ameliorated hepatic fibrosis and accelerated fibrosis regression in mice [157], suggesting that targeting these pathways may represent a promising therapeutic strategy for managing advanced MASLD.